NCT01392235View on ClinicalTrials.gov

Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

August 31, 2016

Conditions
Recurrent Nasopharyngeal CarcinomaMetastatic Nasopharyngeal Carcinoma
Interventions
DRUG

Famitinib

25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Trial Locations (1)

510060

Department of Medical Oncology, Cancer Center, Sun Yet-sen University, Guangzhou

All Listed Sponsors
collaborator

Sun Yat-sen University

OTHER

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT01392235 - Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) | Biotech Hunter | Biotech Hunter